findmyKOL
Clinical trialNCT06193486RecruitingPhase 1Interventional

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment30Metastatic Castration-resistant Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation phase and dose-expansion phase to assess the safety and preliminary efficacy of treatment with autologous T cells genetically modified to express Prostate stem cell antigen.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Daniel Abate-Daga, PhDJad Chahoud, MDJingsong Zhang, MD, PhD →Juskaran Chadha, PhDMonica Chatwal, MDRohit Jain, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Fludarabine →MSGV1-PSCA-8T28Z
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Oct 2024
Primary completion
13 Jan 2029
Completion
13 Dec 2033
Last update posted
31 Mar 2026
Registered enrollment
30
Registry id
NCT06193486
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.